Form 8-K - Current report:
SEC Accession No. 0001213900-22-011983
Filing Date
2022-03-14
Accepted
2022-03-14 07:13:59
Documents
15
Period of Report
2022-03-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea156805-8k_nektarther.htm   iXBRL 8-K 25749
2 PRESS RELEASE TITLED "BRISTOL MYERS SQUIBB AND NEKTAR ANNOUNCE UPDATE ON PHASE 3 ea156805ex99-1_nektartherape.htm EX-99.1 92193
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2916
4 GRAPHIC ex99-1_002.jpg GRAPHIC 1954
  Complete submission text file 0001213900-22-011983.txt   320003

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE nktr-20220314.xsd EX-101.SCH 3027
6 XBRL LABEL FILE nktr-20220314_lab.xml EX-101.LAB 34476
7 XBRL PRESENTATION FILE nktr-20220314_pre.xml EX-101.PRE 22591
9 EXTRACTED XBRL INSTANCE DOCUMENT ea156805-8k_nektarther_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 22735062
SIC: 2834 Pharmaceutical Preparations